Page 25 - Haematologica Vol. 109 - July 2024

EDITORIAL S. Mehra and J. Taylor
Figure 1. How donor T-lymphocyte infusion can lead to neoantigen-specific response in mediastinal germ cell tumors.
heterozygosity were all seen amongst the GCT, hemato- logic malignancy, and sarcoma. Like the multi-headed hydra monster from Greek mythology, mediastinal GCT with secondary somatic tumors tend to come back stron- ger when the heads are chopped off. However, the key to killing the hydra, and possibly to overcoming this often fatal malignancy, is to strike a blow to the common part (the body, or in this case, shared neoantigen).
Despite Genoud et al. successfully demonstrating the potential of donor T-lymphocyte infusions in this case study, there are some limitations to the present findings. Firstly, the study’s reliance on a single patient and lack of a comparative group limits its ability to establish broad conclusions or generalize findings to a larger population. Currently, high-dose chemotherapy and autologous SCT have been used to treat relapsed GCT.10 However, such a treatment regimen has been shown to have patients recur- rently relapsing with hematologic disease, all of which have demonstrated common mutations.8 The findings in this
study argue for the role of allogeneic SCT and also open the doors to further exploration of novel treatments. For example, with the identification of the sarcoma-specific neo-peptide IL36G16-24YPSMCKPIT, there is potential for the development of chimeric antigen receptor (CAR) T-cell therapy which may prove to have efficacy against develop- ment of malignancies in patients with GCT. Additionally, a concern with usage of donor lymphocyte infusions is that patients are at high risk for developing graft-versus-host disease, which has further potential to evolve into chronic disease. Development of alternative therapies that can elicit a neoantigen-specific T-cell response, such as CAR T-cell therapy, which have predominantly acute adverse events, may provide clinicians and patients with better alternatives with regards to therapeutic options.
In conclusion, the study by Genoud et al. provides hope of successful treatment options for patients with medi- astinal GCT refractory to general therapy by using neo- antigen-specific T-cell response following a donor lym-
Haematologica | 109 July 2024
2039